Stay updated on Bardoxolone in CTD-Associated Pulmonary Arterial Hypertension Clinical Trial

Sign up to get notified when there's something new on the Bardoxolone in CTD-Associated Pulmonary Arterial Hypertension Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Bardoxolone in CTD-Associated Pulmonary Arterial Hypertension Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the recommended dose range or evaluation of the change from baseline in 6-minute walk distance (6MWD) for patients with connective tissue disease-associated pulmonary arterial hypertension.
    Difference
    0.1%
    Check dated 2024-06-06T14:47:53.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying inclusion and exclusion criteria for potential participants. Previously, no information was provided under the Participation Criteria section.
    Difference
    33%
    Check dated 2024-05-22T21:28:14.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:26:56.000Z thumbnail image

Stay in the know with updates to Bardoxolone in CTD-Associated Pulmonary Arterial Hypertension Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Bardoxolone in CTD-Associated Pulmonary Arterial Hypertension Clinical Trial page.